These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 32358699)
1. Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. Kim SA; Kim JW; Suh KJ; Chang W; Kim JW; Oh HK; Cho JY; Kim DW; Cho S; Kim JH; Kim K; Kang SB; Jheon S; Lee KW J Cancer Res Clin Oncol; 2020 Sep; 146(9):2399-2410. PubMed ID: 32358699 [TBL] [Abstract][Full Text] [Related]
2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940 [TBL] [Abstract][Full Text] [Related]
3. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720 [TBL] [Abstract][Full Text] [Related]
4. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Heinemann V; von Weikersthal LF; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Miller-Phillips L; Modest DP; Jung A; Kirchner T; Stintzing S Br J Cancer; 2021 Feb; 124(3):587-594. PubMed ID: 33154570 [TBL] [Abstract][Full Text] [Related]
5. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study. Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968 [TBL] [Abstract][Full Text] [Related]
6. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V; Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024 [TBL] [Abstract][Full Text] [Related]
7. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943 [TBL] [Abstract][Full Text] [Related]
8. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156 [TBL] [Abstract][Full Text] [Related]
9. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994 [TBL] [Abstract][Full Text] [Related]
11. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865 [TBL] [Abstract][Full Text] [Related]
12. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). Stahler A; Heinemann V; Holch JW; von Einem JC; Westphalen CB; Heinrich K; Schlieker L; Jelas I; Alig AHS; Fischer LE; Weiss L; Modest DP; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Kirchner T; Jung A; Stintzing S Int J Cancer; 2021 Dec; 149(11):1935-1943. PubMed ID: 34310714 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929 [TBL] [Abstract][Full Text] [Related]
14. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis. Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572 [TBL] [Abstract][Full Text] [Related]
15. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab. Basso M; Dadduzio V; Ardito F; Lombardi P; Strippoli A; Vellone M; Orlandi A; Rossi S; Cerchiaro E; Cassano A; Giuliante F; Barone C Medicine (Baltimore); 2016 May; 95(20):e3722. PubMed ID: 27196492 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807 [No Abstract] [Full Text] [Related]
17. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905 [TBL] [Abstract][Full Text] [Related]
18. XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology. Duran AO; Karaca H; Besiroglu M; Bayoglu IV; Menekse S; Yapici HS; Yazilitas D; Bahceci A; Uysal M; Sevinc A; Hacibekiroglu I; Aksoy A; Tanriverdi O; Arpaci E; Inanc M; Dane F; Ozkan M Asian Pac J Cancer Prev; 2014; 15(23):10375-9. PubMed ID: 25556478 [TBL] [Abstract][Full Text] [Related]
19. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V; Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640 [TBL] [Abstract][Full Text] [Related]
20. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. Modest DP; Denecke T; Pratschke J; Ricard I; Lang H; Bemelmans M; Becker T; Rentsch M; Seehofer D; Bruns CJ; Gebauer B; Modest HI; Held S; Folprecht G; Heinemann V; Neumann UP Eur J Cancer; 2018 Jan; 88():77-86. PubMed ID: 29195117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]